TANAKA Precious Metals to Exhibit at "Medtec China 2023" Medical Device Design and Manufacturing Exhibition, to be Held in Suzhou, China TANAKA PRECIOUS METAL GROUP Co., Ltd. May 30, 2023 14:00 HKT/SGT Read More
TANAKA Precious Metals to Exhibit at "Medtec China 2023" Medical Device Design and Manufacturing Exhibition, to be Held in Suzhou, China TANAKA PRECIOUS METAL GROUP Co., Ltd. May 30, 2023 14:00 HKT/SGT Read More
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma Eisai May 26, 2023 13:15 HKT/SGT Read More
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria Eisai May 25, 2023 20:02 HKT/SGT Read More
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 Eisai May 24, 2023 17:03 HKT/SGT Read More
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、英国（北アイルランドを除く）において早期アルツハイマー病に係る販売承認申請を提出 Eisai May 22, 2023 09:00 JST Read More
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain Eisai May 20, 2023 09:20 HKT/SGT Read More
エーザイ、臨床第III相Clarity AD試験データを用いた、日本における「レカネマブ」の社会的価値について、査読学術専門誌Neurology and Therapy誌に掲載 Eisai May 17, 2023 08:30 JST Read More
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease Eisai May 16, 2023 08:27 HKT/SGT Read More
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration Eisai May 08, 2023 10:15 HKT/SGT Read More
New Data Showing that Transgene and NEC's Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023 NEC Corporation Apr 18, 2023 16:13 HKT/SGT Read More
アバンセ・クリニカルのCEOが2023年エボリューション・ヨーロッパ・サミットのグローバル・バイオファーマ・パネルに参加 Avance Clinical Apr 18, 2023 11:00 JST Read More
Eisai Completes a Major Renovation of Tsukuba Research Laboratories Eisai Apr 06, 2023 17:32 HKT/SGT Read More
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal Eisai Apr 04, 2023 12:23 HKT/SGT Read More
エーザイ、臨床第III相Clarity AD試験データを用いた「レカネマブ」の長期的健康アウトカムについて、シミュレーションを用いた評価結果が査読学術専門誌Neurology and Therapy誌に掲載 Eisai Apr 04, 2023 12:00 JST Read More
Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on "Patient-Proposed Healthcare Services" System Eisai Apr 03, 2023 12:06 HKT/SGT Read More
エーザイ、抗がん剤タゼメトスタットについて、「患者申出療養」制度に基づく医師主導臨床研究への協力に関する契約を国立がん研究センターと締結 Eisai Apr 03, 2023 10:00 JST Read More
